Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
Open Access
- 1 September 2020
- journal article
- research article
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 12, 515-526
Abstract
Background and Aim: Thrombocytopenia is common in people with chronic liver disease, who frequently undergo invasive procedures. To minimize the risk of bleeding, prophylactic platelet transfusions have traditionally been used but carry many risks. The aim of this study was to evaluate the cost-effectiveness of avatrombopag compared with platelet transfusion and lusutrombopag as a treatment for thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a medical procedure. Methods: A decision-tree model was developed from a US payer perspective to capture acute events observed in phase 3 global randomized controlled clinical trials and, to support exploratory analyses, potential longer-term complications resulting from a major bleed or thromboembolic event. Treatment costs were taken from publicly available data sources. The interventions were evaluated in the overall trial populations and in subpopulations with higher and lower baseline platelet counts. Results were presented as incremental cost per platelet transfusion avoided. One-way and probabilistic sensitivity analyses were conducted. Results: In the overall population, avatrombopag reduced the need for platelet transfusions and produced cost-savings compared with platelet transfusion (80% fewer prophylactic platelet transfusions, $4250 lower costs) and lusutrombopag (42% fewer prophylactic platelet transfusions, $5819 lower costs). Similar results were seen in both the higher and lower platelet count subpopulations. The one-way and probabilistic sensitivity analyses found that the use of avatrombopag is cost-saving with the incremental cost-effectiveness ratio in quadrant IV (decreased costs, prophylactic platelet transfusions avoided). Conclusion: The use of avatrombopag is expected to be cost-saving while reducing the need for prophylactic platelet transfusions compared with platelet transfusion and lusutrombopag.Keywords
This publication has 25 references indexed in Scilit:
- Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part II: RecommendationsJournal of Vascular and Interventional Radiology, 2019
- Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)Hepatology, 2019
- Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and ThrombocytopeniaGastroenterology, 2018
- Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective proceduresJournal of Medical Economics, 2018
- Platelets in liver disease, cancer and regenerationWorld Journal of Gastroenterology, 2017
- Oral Surgical Treatment of Patients With Chronic Liver Disease: Assessments of Bleeding and Its Relationship With Thrombocytopenia and Blood Coagulation ParametersJournal of Oral and Maxillofacial Surgery, 2017
- Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedureJournal of Hepatology, 2014
- Thrombocytopenia: an updateInternational Journal of Laboratory Hematology, 2014
- Review article: thrombocytopenia in chronic liver diseaseAlimentary Pharmacology & Therapeutics, 2007
- Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment optionsAlimentary Pharmacology & Therapeutics, 2006